SAMHD1 and acute myeloid leukemia: Since SAMHD1 limits the efficacy of cytarabine by hydrolyzing the active metabolite, Ara-CTP, it could be hypothesized that cases with high frequency of SAMHD1 expressing cells are less sensitive to this essential therapeutic component, similar to findings in acute myeloid leukemia [10, 18–20].